Skip to Content
You are currently on the new version of our website. Access the old version .

13 Results Found

  • Article
  • Open Access
34 Citations
8,712 Views
8 Pages

Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders

  • María Fernández-Trapero,
  • Carmen Pérez-Díaz,
  • Francisco Espejo-Porras,
  • Eva de Lago and
  • Javier Fernández-Ruiz

11 February 2020

The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment of spasticity and pain in multiple sclerosis patients and is being investigated for other central and peripheral pathological conditions. It may also serve in Ve...

(This article belongs to the Special Issue The Endocannabinoid System in Health and Disease)
  • Article
  • Open Access
658 Views
20 Pages

Effects of Sativex® Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial

  • Olivia Bornæs,
  • Rikke Lundsgaard Nielsen,
  • Louise Westberg Strejby Christensen,
  • Ida Klitzing Storgaard and ,
  • Thomas Kallemose,
  • Helle Gybel Juul-Larsen,
  • Juliette Tavenier,
  • Baker Jawad,
  • Ove Andersen and
  • Mette Merete Pedersen
  • + 11 authors+ 6 authors

11 July 2026

Background: Poor appetite, a major contributor to malnutrition, is highly prevalent among older adults and associated with adverse clinical outcomes. Nevertheless, there are currently no widely accepted or consistently effective pharmacological treat...

(This article belongs to the Section Geriatric Nutrition)
  • Article
  • Open Access
35 Citations
8,315 Views
12 Pages

Several cannabinoids afforded neuroprotection in experimental models of Huntington’s disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either ∆9-tetrahydrocannabinol (∆9-THC) or cannabidiol (CBD), which are the...

(This article belongs to the Special Issue Cannabinoid Signaling in Nervous System)
  • Article
  • Open Access
35 Citations
10,720 Views
12 Pages

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

  • Mara Turri,
  • Francesco Teatini,
  • Francesco Donato,
  • Giampietro Zanette and ,
  • Valeria Tugnoli,
  • Luciano Deotto,
  • Bruno Bonetti and
  • Giovanna Squintani
  • + 3 authors+ 0 author

Background. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (nabiximols or Sativex®) is an oromucosal spray formulation containing THC and CBD at an approximately 1:1 fixed ratio. Its administration for the treatment of pain in patients with...

(This article belongs to the Special Issue Cannabinoids for Medical Use)
  • Article
  • Open Access
9 Citations
4,521 Views
20 Pages

Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples

  • Anne Scheunemann,
  • Katrin Elsner,
  • Tanja Germerott,
  • Sergiu Groppa and ,
  • Cornelius Hess,
  • Isabelle Miederer,
  • Alicia Poplawski and
  • Jörg Röhrich
  • + 3 authors+ 0 author

Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medic...

(This article belongs to the Special Issue Metabolite Analysis in Forensic Toxicology)
  • Article
  • Open Access
10 Citations
5,864 Views
9 Pages

Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study

  • Rosaria Sacco,
  • Gianna Carla Riccitelli,
  • Giulio Disanto,
  • Julien Bogousslavsky and ,
  • Ariane Cavelti,
  • David Czell,
  • Christian Philipp Kamm,
  • Uta Kliesch,
  • Simon Peter Ramseier and
  • Chiara Zecca
  • + 6 authors+ 1 author

14 May 2024

Background: Cannabinoid oro-mucosal spray nabiximols is approved for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other antispastic medications. Few real-world data are available on the effectiveness, safety and p...

(This article belongs to the Special Issue Multiple Sclerosis: Diagnosis, Treatment and Clinical Management)
  • Review
  • Open Access
14 Citations
7,759 Views
28 Pages

Medical Cannabis in Pediatric Oncology: Friend or Foe?

  • Megan Malach,
  • Igor Kovalchuk and
  • Olga Kovalchuk

16 March 2022

The antineoplastic effects of cannabis have been known since 1975. Since the identification of the components of the endogenous cannabinoid system (ECS) in the 1990s, research into the potential of cannabinoids as medicine has exploded, including in...

(This article belongs to the Special Issue Cannabidiol: Advances in Therapeutic Applications and Future Perspectives)
  • Systematic Review
  • Open Access
1,445 Views
21 Pages

Nabiximols in Multiple Sclerosis: Beyond Spasticity—An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes

  • Dénes Kleiner,
  • István László Horváth,
  • Dóra Mátis,
  • Rita Nagy and ,
  • Dorottya Gergő,
  • Katalin Lugosi,
  • Gábor Fazekas,
  • Péter Fehérvári,
  • Péter Hegyi and
  • Dezső Csupor
  • + 5 authors+ 0 author

25 June 2026

Background/Objectives: Nabiximols, a standardized extract of Cannabis sativa, has been approved as an add-on therapy for patients with moderate to severe spasticity associated with multiple sclerosis (MS). Moreover, current Italian treatment algorith...

(This article belongs to the Section Neurosciences)
  • Review
  • Open Access
10 Citations
8,768 Views
28 Pages

30 December 2022

The analgesic potential of Cannabis sativa L.—based medicinal cannabis products for treatment of cancer associated chronic pains has gained increased interest in recent years. To ensure a controlled distribution of these products and investigat...

(This article belongs to the Topic Cannabis, Cannabinoids and Its Derivatives)
  • Review
  • Open Access
3 Citations
4,114 Views
28 Pages

Cannabidiol in Neurology: Current Insights and Translational Perspectives

  • Magdalena Białoń,
  • Marta Kędziora and
  • Katarzyna Starowicz

17 February 2026

Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last fe...

(This article belongs to the Special Issue The Therapeutic Potential of Cannabidiol)
  • Review
  • Open Access
63 Citations
11,912 Views
20 Pages

25 October 2020

Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has...

(This article belongs to the Special Issue Role of Cannabinoids in Inflammation)
  • Systematic Review
  • Open Access
29 Citations
24,830 Views
32 Pages

Despite current therapeutic strategies for immunomodulation and relief of symptoms in multiple sclerosis (MS), remyelination falls short due to dynamic neuropathologic deterioration and relapses, leading to accrual of disability and associated patien...

(This article belongs to the Special Issue New Advances and Challenges in Multiple Sclerosis: Pathophysiology and Therapeutic Strategies)
  • Review
  • Open Access
34 Citations
8,976 Views
24 Pages

27 November 2024

Cannabis sativa L. contains numerous compounds with antioxidant and anti-inflammatory properties, including the flavonoids and the cannabinoids, particularly Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids have an effect on t...

(This article belongs to the Special Issue Molecular Insight into Plant Bioactive Compounds)